0.8743
price up icon1.66%   0.0143
after-market Handel nachbörslich: .87 -0.0043 -0.49%
loading

Kronos Bio Inc Aktie (KRON) Neueste Nachrichten

pulisher
Nov 21, 2024

Petri Dish: Kronos Bio seeks merger; Former Biogen R&D head joins investment firm - The Business Journals

Nov 21, 2024
pulisher
Nov 20, 2024

Kronos Bio downgraded by Piper Sandler, TD Cowen - MSN

Nov 20, 2024
pulisher
Nov 16, 2024

Kronos Bio Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 16, 2024
pulisher
Nov 15, 2024

Kronos Bio Provides Update on Review of Strategic Alternatives - Marketscreener.com

Nov 15, 2024
pulisher
Nov 15, 2024

Kronos Bio shares downgraded to hold by TD Cowen - Investing.com India

Nov 15, 2024
pulisher
Nov 14, 2024

Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 - The Manila Times

Nov 14, 2024
pulisher
Nov 14, 2024

Kronos Bio Highlights Preclinical Data that Show p300 KAT - GlobeNewswire

Nov 14, 2024
pulisher
Nov 14, 2024

Kronos Bio's KB-7898 Shows 50% Reduction in Inflammation Markers in Preclinical Study | KRON Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 14, 2024

Kronos Bio stock takes a hit with piper sandler slashing price target - Investing.com

Nov 14, 2024
pulisher
Nov 14, 2024

Kronos mulls ‘strategic alternatives’ after axing cancer drug development - Pharmaceutical Technology

Nov 14, 2024
pulisher
Nov 14, 2024

Kronos Bio (NASDAQ:KRON) Rating Lowered to "Hold" at TD Cowen - MarketBeat

Nov 14, 2024
pulisher
Nov 14, 2024

Kronos Bio downgraded by Piper Sandler, TD Cowen (NASDAQ:KRON) - Seeking Alpha

Nov 14, 2024
pulisher
Nov 14, 2024

TD Cowen Downgrades Kronos Bio (KRON) - MSN

Nov 14, 2024
pulisher
Nov 13, 2024

Kronos Bio earnings beat by $0.05, revenue topped estimates - Investing.com UK

Nov 13, 2024
pulisher
Nov 13, 2024

Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance

Nov 13, 2024
pulisher
Nov 13, 2024

Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives - The Manila Times

Nov 13, 2024
pulisher
Nov 13, 2024

Kronos Bio Reports Third Quarter 2024 Financial Results and - GlobeNewswire

Nov 13, 2024
pulisher
Nov 13, 2024

Kronos Bio Halts Cancer Drug Trial, Explores Strategic Alternatives Amid Safety Concerns | KRON Stock News - StockTitan

Nov 13, 2024
pulisher
Nov 10, 2024

Kronos Bio's Market Cap Drops To US$50m Leaving Insiders With Losses - Simply Wall St

Nov 10, 2024
pulisher
Nov 07, 2024

Kronos Bio faces Nasdaq delisting over share price - Investing.com India

Nov 07, 2024
pulisher
Nov 07, 2024

Kronos Bio faces Nasdaq delisting over share price By Investing.com - Investing.com UK

Nov 07, 2024
pulisher
Nov 06, 2024

Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma - GlobeNewswire

Nov 06, 2024
pulisher
Nov 05, 2024

Kronos Bio to Present Breakthrough Multiple Myeloma Treatment Data at ASH 2024 | KRON Stock News - StockTitan

Nov 05, 2024
pulisher
Nov 04, 2024

Non-Hodgkin’s Lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Nov 04, 2024
pulisher
Nov 04, 2024

TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail

Nov 04, 2024
pulisher
Nov 02, 2024

Kronos Bio, Inc. (NASDAQ:KRON) Sees Large Decline in Short Interest - Defense World

Nov 02, 2024
pulisher
Nov 01, 2024

Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace

Nov 01, 2024
pulisher
Oct 30, 2024

Non-Hodgkin Lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Oct 30, 2024
pulisher
Oct 29, 2024

Nio Inc ADR (NIO-N) QuotePress Release - The Globe and Mail

Oct 29, 2024
pulisher
Oct 29, 2024

Phillips-Van Heusen Corp (PVH-N) QuotePress Release - The Globe and Mail

Oct 29, 2024
pulisher
Oct 25, 2024

After Plunging -23.49% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON) - MSN

Oct 25, 2024
pulisher
Oct 23, 2024

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors - The Manila Times

Oct 23, 2024
pulisher
Oct 23, 2024

Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium - GlobeNewswire

Oct 23, 2024
pulisher
Oct 23, 2024

Taylor Morrison Home Corp (TMHC-N) QuotePress Release - The Globe and Mail

Oct 23, 2024
pulisher
Oct 09, 2024

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven Tumors - The Manila Times

Oct 09, 2024
pulisher
Oct 09, 2024

Kronos Bio to Present Data at the EORTC-NCI-AACR Symposium - GlobeNewswire

Oct 09, 2024
pulisher
Oct 08, 2024

Kronos Bio's (KRON) "Overweight" Rating Reaffirmed at Piper Sandler - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

Kronos Bio nominates KAT inhibitor as development candidate for Sjögren’s disease - BioWorld Online

Oct 08, 2024
pulisher
Oct 08, 2024

Piper Sandler maintains Overweight rating on Kronos Bio shares - Investing.com

Oct 08, 2024
pulisher
Oct 08, 2024

Kronos Bio nominates KB-7898 for autoimmune disease treatment - Investing.com

Oct 08, 2024
pulisher
Oct 07, 2024

Kronos Bio nominates KB-7898 for autoimmune disease treatment By Investing.com - Investing.com South Africa

Oct 07, 2024
pulisher
Oct 07, 2024

Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren's Disease - The Manila Times

Oct 07, 2024
pulisher
Oct 07, 2024

Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease - GlobeNewswire

Oct 07, 2024
pulisher
Oct 01, 2024

Plexium Announces Appointment of Jorge F. DiMartino, M.D., Ph.D. as Chief Medical Officer - PR Newswire

Oct 01, 2024
pulisher
Sep 29, 2024

Kronos Bio, Inc. (NASDAQ:KRON) Position Increased by Forefront Analytics LLC - Defense World

Sep 29, 2024
pulisher
Sep 25, 2024

Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy - StockTitan

Sep 25, 2024
pulisher
Sep 25, 2024

Kronos Bio to Present Data at ACR Convergence 2024 to - GlobeNewswire

Sep 25, 2024
pulisher
Sep 23, 2024

Keros Therapeutics (NASDAQ:KROS) Shares Gap Up to $55.80 - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Avoro Capital Advisors LLC Reduces Position in Krystal Biotech, Inc. (NASDAQ:KRYS) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Integral Health Asset Management LLC Acquires 45,000 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

How the (KROS) price action is used to our Advantage - Stock Traders Daily

Sep 23, 2024
pulisher
Sep 23, 2024

How does Keros Therapeutics Inc (KROS) change from a tortoise to a hare? - SETE News

Sep 23, 2024
$70.39
price down icon 0.93%
$18.42
price down icon 1.07%
$38.25
price up icon 3.55%
$367.36
price up icon 0.83%
$194.56
price up icon 0.15%
$108.23
price up icon 5.96%
Kapitalisierung:     |  Volumen (24h):